ClinicalTrials.gg
CompletedNCT02017860Updated Apr 30, 2020Results posted

Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.

A Phase 2 interventional study of Everolimus in Neoplasms, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to collect and assess long-term safety of everolimus in patients who were currently receiving everolimus treatment in a Novartis-sponsored, Oncology CD\&MA study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol, and were unable to access everolimus treatment outside of a clinical study. Parent studies eligible to participate in the roll-over study were decided by Novartis. Investigator initiated trials (IITs) were not included. The primary objective of the parent study must have been reached and the parent study must have been in the process of being completed and reported.

Read the detailed description

This was a multi-center, open label study to collect and assess long-term safety of everolimus in patients being treated in current Novartis-sponsored studies and who were benefiting from treatment with everolimus judged by the investigator.There was no screening period for this study. Eligible patients were consented and started their treatment with everolimus as soon as they entered the study. Patients had to return to the study center on a yearly basis (± 3 months), but for resupply of study medication, the frequency of the receipt and dispensing followed local practice (e.g., every 2 to 3 months). The dose of everolimus was based on the investigator's judgment.

Adverse events (AEs) were collected continuously throughout the study. For the safe and effective use of everolimus, patient could return to the clinic at any given time following local practice. When AEs were observed, additional visits were arranged by investigator's discretion.

Patients continued to be treated until they were no longer benefiting from everolimus as defined in the parent protocol (disease progression), developed unacceptable toxicities, withdrew consent, were non-compliant to the protocol, the investigator felt it is no longer in the patient's best interest to continue everolimus therapy or the patient died, whichever came first.

A patient reached the end of study when everolimus treatment was permanently discontinued and the end of treatment visit had been performed. All patients were followed for AEs for 30 days after the last dose of everolimus.

The study remained open for approximately 5 years; until such time that enrolled patients no longer needed treatment with everolimus, whichever came first.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • RAD001, everolimus, roll-over
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 4 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is currently enrolled in a Novartis-sponsored, CD\&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their requirements in the parent study
  • Patient is currently benefiting from treatment with everolimus, as determined by the guidelines of the parent protocol.

Exclusion criteria

Exclusion Criteria:

  • Patient has been permanently discontinued from everolimus study treatment in the parent study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Everolimus

    Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.

    Drug: Everolimus

Interventions

  • Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.

06

What researchers measure

Primary outcomes

  1. Number of Pariticipants With Adverse Events as a Measure of Safety and Tolerability

    Any sign or symptom that occurs during the study treatment plus the 30 days post treatment.

    Time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approximately 5 years.

07

Results

Posted Apr 30, 2020

Participant flow

A total of 4 subjects were enrolled in the study and received at least one dose of everolimus. Of the 4 subjects, 2 subjects terminated treatment due to study closure by sponsor as approximately 5 years had elapsed since first patient first visit (FPFV). One subject terminated treatment due to an Adverse Event (AE) and one subject withdrew consent.

Participant flow — Overall Study
MilestoneEverolimus
Started4
Completed2
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Pariticipants With Adverse Events as a Measure of Safety and Tolerability

Any sign or symptom that occurs during the study treatment plus the 30 days post treatment.

Time frame:
Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approximately 5 years.
Reported as:
Number · Count of Participants
Number of Pariticipants With Adverse Events as a Measure of Safety and Tolerability
Count of ParticipantsEverolimus
Participants who had at least one Adverse Event4
Participants with Grade 3/4 Adverse Event2

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approximately 5 years.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus0/4 (0%)1/4 (25%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventEverolimus
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/4
Pleural effusionRespiratory, thoracic and mediastinal disorders1/4
Most frequent other events
Showing 10 of 32
Most frequent other events
EventEverolimus
Pericardial effusionCardiac disorders2/4
StomatitisGastrointestinal disorders2/4
Oedema peripheralGeneral disorders2/4
RhinitisInfections and infestations2/4
Blood creatinine increasedInvestigations2/4
HyperlipidaemiaMetabolism and nutrition disorders2/4
PneumonitisRespiratory, thoracic and mediastinal disorders2/4
AlopeciaSkin and subcutaneous tissue disorders2/4
Nail disorderSkin and subcutaneous tissue disorders2/4
Dental cariesGastrointestinal disorders1/4

Baseline characteristics

All 4 subjects were included in both the Full Analysis Set and Safety Set.

Age, Categorical
Age, Categorical(Participants)Everolimus
<=18 years0
Between 18 and 65 years3
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus
Female2
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Everolimus
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Novartis Investigative Site
    Matsuyama, Ehime 791-0280, Japan
  • Novartis Investigative Site
    Sapporo city, Hokkaido 060 8648, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 540-0006, Japan
  • Novartis Investigative Site
    Kitaadachi-gun, Saitama 362-0806, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Apr 2019, 63 months.

Results were first posted in Apr 2020, 1 year after primary completion.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 63 months is above that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2013
First posted
Dec 23, 2013
StartActual
Jan 16, 2014
Primary completionActual
Apr 25, 2019
CompletionActual
Apr 25, 2019
Results first posted
Apr 30, 2020
Last update
Apr 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02017860
Responsible party
Sponsor
First posted
Dec 23, 2013
Start date
Jan 16, 2014
Primary completion
Apr 25, 2019
Completion
Apr 25, 2019
Results posted
Apr 30, 2020
Last update
Apr 30, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion